title: True alignment of preclinical and clinical research to enhance success in CNS drug development: a review of the current evidence.
abstract: Central nervous system pharmacological research and development has reached a critical turning point. Patients suffering from disorders afflicting the central nervous system are numerous and command significant attention from the pharmaceutical industry. However, given the numerous failures of promising drugs, many companies are no longer investing in or, indeed, are divesting from this therapeutic area. Central nervous system drug development must change in order to develop effective therapies to treat these patients. Preclinical research is a cornerstone of drug development; however, it is frequently criticised for its lack of predictive validity. Animal models and assays can be shown to be more predictive than reported and, on many occasions, the lack of thorough preclinical testing is potentially to blame for some of the clinical failures. Important factors such as translational aspects, nature of animal models, variances in acute versus chronic dosing, development of add-on therapies and understanding of the full dose-response relationship are too often neglected. Reducing the attrition rate in central nervous system drug development could be achieved by addressing these important questions before novel compounds enter the clinical phase. This review illustrates the relevance of employing these criteria to translational central nervous system research, better to ensure success in developing new drugs in this therapeutic area.
authors.affiliation: Cognition Research Group, Takeda Cambridge Ltd, Cambridge, UK pascal.goetghebeur@synaging.com.
authors.forename: Pascal Jd
authors.initials: PJ
authors.lastname: Goetghebeur
authors.affiliation: CNS Therapeutic Area Unit, Takeda Development Centre Europe Ltd, London, UK.
authors.forename: Jina E
authors.initials: JE
authors.lastname: Swartz
mesh_terms: D000818:Animals; D035843:Biomedical Research / Q000379:methods; D002491:Central Nervous System Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D055808:Drug Discovery / Q000379:methods; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004345:Drug Industry / Q000379:methods; D006801:Humans; D057170:Translational Research, Biomedical / Q000379:methods
chemical_list: D002491:Central Nervous System Agents
keywords: CNS; U-shape; translation